Eculizumab improves fatigue in refractory generalized myasthenia gravis
Henning Andersen(Aarhus University Hospital), Érica Nogueira Coelho, David Feder, Renata Martins Ribeiro, Alzira Alves de Siqueira Carvalho(Centro Universitário Fundação Santo André), Jan Vynckier(Valve (United States)), Philip Van Damme(Universitair Ziekenhuis Leuven), Annelies Vanhee, Guy Van den Abeele, Luiz Augusto da Silva, Kathy de Koning, Nicolas Vandenbussche(Ghent University Hospital), Mariela Bettini, Caroline Schotte, Fanny O’Brien(Alexion Pharmaceuticals (United States)), Délphine Mahieu, Juliet Saba, Maria da Penha Ananias Morita, Renato Mantegazza(Italian Association for Cancer Research), Miguel Wilken, Bruno Bezerra Rosa, Thabata Veiga, James F. Howard(University of North Carolina at Chapel Hill), Gonzalo Vidal, Fábio Barroso(Université Paris-Sud), Rudy Mercelis, Pamela César, Ana Paula Souto Melo(University of Washington), Charlotte Smetcoren, Sarah Verjans, Petra Tilkin, Ann D’Hondt(KU Leuven), Olivier Stevens, Linda Wagemaekers, Igor Dias Brockhausen, Alejandra Dalila Garcia, Marcelo Rugiero, Rosana Rocha, Jan De Bleecker(Ghent University Hospital), Katrien De Mey, Claudio Mazia, Annelies Depreitere, Sien Van Daele, Daniel Ambrosio, Jing Jing Wang(South Australia Pathology), Marcelo Chaves, Murilo Santos Engel, Kaushik Patra, Jordana Gonçalves Geraldo
Cited by 58
Related Papers
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
|The Lancet Neurology|2017|820
Burden of disease in Brazil, 1990–2016: a systematic subnational analysis for the Global Burden of Disease Study 2016
|The Lancet|2018|460
239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018
|Neuromuscular Disorders|2019|308